© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy
June 17, 2025
For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.
How Americans Think and Feel About Their Medical Devices: New Survey Findings
June 16, 2025
Among 2000 US adults, a new survey found consumers prioritize trust and recommendations over brand loyalty in health tracking devices, prizing accuracy and reliability.
Solriamfetol Improves OSA-Related Cognitive Deficits Independent of Sleepiness Reduction
June 16, 2025
Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.
Topical Steroid Withdrawal vs Atopic Dermatitis Flare: Parsing the Differences with Brad Glick, DO, MPH
June 16, 2025
RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.
Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma
June 16, 2025
The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.
Key Updates in Atopic Dermatitis for Primary Care
June 13, 2025
Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.
Late-Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals
June 13, 2025
Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.
Novo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity
June 13, 2025
Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.
FDA Expands Label for Moderna's mRNA RSV Vaccine to Include At-Risk Adults Aged 18 to 59 Years
June 13, 2025
mRNA1345 (mResvia) is now indicated for adults aged 18 to 59 years with underlying conditions including cardiovascular, respiratory, and endocrine disorders.
GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose
June 13, 2025
Your daily dose of the clinical news you may have missed.